IBE
print


Navigationspfad


Inhaltsbereich

Berger, Dr. Ursula

  • Schutzmeier P, Berger U, Bose-O'Reilly S. (2016). Gold mining in Ecuador: A cross-sectional assessment of mercury in urine and medical symptoms in miners from Portovelo/Zaruma. Mercury and Health: Current Perspectives and Future Directions. Int J Environ Res Public Health, 2016 Dec 30;14(1).
  • Doering S, Bose-O'Reilly S, Berger U. (2016). Essential Indicators Identifying Chronic Inorganic Mercury Intoxication: Pooled Analysis across Multiple Cross-Sectional Studies. PLoS One. 2016 Aug 30;11(8)
  • Herrera R, Radon K, von Ehrenstein OS, Cifuentes S, Muñoz DM, Berger U. (2016). Proximity to mining industry and respiratory diseases in children in a community in Northern Chile: A cross-sectional study. Environmental Health. 2016 Jun 7;15(1):66.
  • Vogt, S., Mielck, A., Berger, U., Grill, E., Peters, A., Döring, A., Holle, R., Strobl, R., Zimmermann, A., Linkohr, B., Wolf, K., Kneißl, K., Maier, W. (2015). Neighborhood and healthy aging in a German city: distances to green space and senior service centers and their associations with physical constitution, disability and health related quality of life. European Journal of Ageing, Volume 12, Issue 4, pp.273-283.
  • Razum O, Voigtländer S, Berger U. (2014). Explaining health inequalities: the role of space and time. Editorial. Int J Public Health, 2014 Jun; 59(3):425-6
  • Albers L, Heinen F, Landgraf M, Straube A, Blum B, Filippopulos F, Lehmann S, Mansmann U, Berger U, Akboga Y, von Kries R. (2014): Headache cessation by an educational intervention in grammar schools: a cluster randomized trial. European Journal of Neurology 2015, Volume 22, Issue 2, pp. 270-6.
  • Clark T, Berger U, Mansmann U (2013). Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review. BMJ 2013; 346:f1135.
  • Voigtländer S, , Razum O, Berger U (2013). Methods to Measure Neighbourhoods and Analyse Their Impact on Health: An Overview. In: Neighbourhood Structure and Health Promotion, 2013, Springer New York Heidelberg Dordrecht London, ISBN 978-1-4614-6671-0
  • Reiss K, Berger U, Winkler V, Voigtländer S, Becher H, Razum O (2013): Assessing the effect of regional deprivation on mortality avoiding compositional bias: a natural experiment. J Epidemiol Community Health 2013; 67: 213–218.
  • Berger U, Razum O, Voigtländer S (2011): Der Einfluss regionaler und nachbarschaftlicher Deprivation auf körperliche Gesundheit in Deutschland. In: Dokumentation 16. Kongress Armut und Gesundheit – Verwirklichungschancen für Gesundheit. Berlin: Gesundheit Berlin-Brandenburg.
  • Voigtländer S, Goebel J, Claßen T, Wurm M, Berger U, Strunk A, Elbern H (2011): Using geographically referenced data on environmental exposures for public health research: a feasibility study based on the German Socio-Economic Panel Study (SOEP). SOEPpapers 386/2011Epub: Juli 2011.
  • Wolf VC, Berger U, Gassmann A, Müller C (2011) High chemical diversity of a plant species is accompanied by increased chemical defence in invasive populations. Biological Invasions, 13: 2091-2102
  • Voigtländer S, Berger U, Razum O. (2010). The impact of regional and neighbourhood deprivation on physical health in Germany: a multilevel study. BMC Public Health, 2010 Jul 8;10:403.
  • Voigtländer S, Berger U, Razum O. (2009). Zunehmende regionale Unterschiede bei den Lebensverhältnissen in Deutschland und ihre Bedeutung für die Erklärung gesundheitlicher Ungleichheit. Gesundheitswesen, 2010 May; 72(5), pp.301-8. Epub: 2009 Aug 6. German.
  • Berger U, Der G, Mutrie N, Hannah MK (2005). The impact of retirement on physical activity. Aging and Society, 25, pp. 181-195.
  • Häussler B, Berger U, Mast O, Thefeld W. (2005). Risk and potential risk reduction in diabetes type 2 patients in Germany. European Journal of Health Economics, Vol. 6, pp. 152-158.
  • Cadicamo CD, Mortier J, Wolber G, Hell M, Heinrich IE, Michel D, Semlin L, Berger U, Korting HC, Höltje HD, Koksch B, Borelli C (2012). Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues adressing different secreted aspartic proteinases of Candida albicans. Biochem Pharmacol. 2012 Dec 20. doi:pii: S0006-2952(12)00794-0. 10.1016/j.bcp.2012.12.008.
  • Schaller M, Borelli C, Berger U, Walker B, Schmidt S, Weindl G, Jäckel A. (2009). Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection. Medical Mycology, 47:7,pp. 753-758.
  • Borelli S, Monn A, Meyer J, Berger U, Honegger HP, Lautenschlager S. (2009). Evaluation of a Particle Gel Immunoassay as a Screening Test for Syphilis. Infection, 37(1):26-8.
  • Borelli C, Merk K, Schaller M, Jacob K, Vogeser M, Weindl G, Berger U, Plewig G. (2006). In vivo porphyrin production by P. acnes in untreated acne patients and its modulation by acne treatment. Acta Derm Venereol., 86(4), pp. 316-319.
  • Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Präuer H. (2004). Factors influencing survival after resection of pulmonary metastases from colorectal cancer. British Journal of Surgery, 91 (8), pp. 1066-1071.
  • Häussler B, Berger U. (2004). Blühende Landschaften: Die Effektivität von Disease-Management-Programmen in der Wahrnehmung deutscher EBM-Experten. Gesundheits- und Sozialpolitik, 58, pp. 48-55.
  • Häussler B, Berger U. (2004). Bedingungen für effektive Disease-Management-Programme. Analyse, Bewertung und Lösungsansätze für Qualität und Finanzierung. Beiträge zum Gesundheitsmanagement, Bd. 7, Nomos Verlagsgesellschaft, Baden-Baden.
  • Mutrie N, Hannah MK, Berger U. (2003). The relationship among different modes of physical activity and non-clinical depression. Journal of Sports Sciences, 21 (4), p. 355.
  • Berger U. (2003). Exploring Time-Variation in Survival Models. Logos Verlag, Berlin.
  • Berger U, Schäfer J, Ulm K. (2003). Dynamic Cox Modelling based on Fractional Polynomials: Time-Variations in Gastric Cancer Prognosis. Statistics in Medicine, 22(7), pp. 1163-1180.
  • Kauermann G, Berger U. (2003). A smooth test in proportional hazard models using local partial likelihood fitting. Lifetime Data Analysis, 9, pp. 373-393.
  • Berger U, Mutrie N. (2002). Bayesian Modelling of Physical Activity in Scotland. Proceedings of the 17th International Workshop on Statistical Modelling, pp. 299-303.
  • Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jürchott K, Schmitt M, Royer HD. (2002). Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. International Journal of Cancer, 97(3), pp. 278-282.
  • Ulm K, Nekarda H, Gerein P, Berger U. (2001). Statistical Methods to Identify Prognostic Factors. In: Handbook of Statistics in Clinical Oncology, Marcel Dekker INC, New York.
  • Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M. (2001) Prognostic impact of proteolytic factors (urikoinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clinical Cancer Research, 7, pp. 2757-2764.
  • Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. (2001). Expression of Latent Matrix Metalloproteinase-9 (MMP-9) Predicts Survival in Advanced Ovarian Cancer. Gynecologic Oncology, 82, pp. 291-298.
  • Prechtel D, Harbeck N, Berger U, Höfler H, Werenskiold AK. (2001). Clinical relevance of T1-S, an oncogene-inducible, secreted glycoprotein of the immunoglobulin superfamily, in node-negative breast. Lab Invest, 81(2), pp. 159-165.
  • Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. (2001). Increased Expression of Matrix Metalloproteinases MMP-2, MMP-9 and the Urokinase-type Plasminogen Activator is Associated with Progression from Benign to Advanced Ovarian Cancer. Clinical Cancer Research, 7, pp. 2396-2404.
  • Sendler, A., Gilbertz, K.-P., Becker, I., Berger, U., Mueller, J., Fink, U., van Beuningen, D., Siewert, J. R. (2001). Proliferation kinetics and Prognosis in gastric cancer after Resection. European Journal of Cancer, 37, pp. 1635-1641.
  • Berger, U. (2000). Model Choice in the Bayesian Framework. Proceedings of the 15th International Workshop on Statistical Modelling, pp. 328-331.
  • Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M. (2000). Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int. Journal of Biol. Markers, 15(1), pp. 79-83.
  • Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Höfler H, Jänicke F, Graeff H, Schmitt M. (1999). Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. British Journal of Cancer, 80, pp. 419-426.
  • Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M. (1999). Invasion marker PAI-1 remains strong prognostic factor after long-term follow-up both for primary cancer and following first relapse. Breast Cancer Research and Treatment, 54,pp. 147-157.
  • Schmalfeldt B, Kuhn W, Harbeck N, Späthe K, Dettmar P, Berger U, Schmitt M, Graeff H. (1999): Invasions- und Proliferationsfaktoren bei LMP-Tumoren des Ovars: Mögliche Konsequenzen für die Klinik. Geburtsh. und Frauenheilk., 59, pp. 507-512.
  • Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H. (1999). Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. British Journal of Cancer, 79, pp. 1746-1751.
  • Jänicke F, Thomssen C, Harbeck N, Prechtl A, Berger U, Ulm K, Dettmar P, Pache L, Schmitt M, Graeff H. (1998). Tumorbiological factors (uPA, PAI-1) as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. European Journal of Cancer, 34, p. 45 Suppl. 1.
  • Ulm K, Berger U. (1998). Prognose in der Onkologie: Die Erkennung und Bewertung prognostischer Faktoren. TUM - Mitteilungen der Technischen Universität München, 5-97/98.
  • Berger U, Ulm K et. al. (1997). Identifying time-varying effects of prognostic factors in breast cancer patients. Breast Cancer Research and Treatment, Lippman M. E. (Editor), Kluwer Academic Publishers, 41.
  • Berger U. (1996). Agriculture in the three new Member States: Austria, Finland and Sweden. Statistics in Focus, Agriculture, Forestry and Fisheries, 1996-7, EUROSTAT, Statistical office of the European Communities, Luxembourg. (Also in: Statistische Diskussionsbeiträge, 4, Universität Potsdam.)
  • Berger U. (1996). Die Methoden der EU zur Beurteilung der Einkommenssituation in der Landwirtschaft: Am Beispiel der Bundesrepublik Deutschland. 1996. Statistische Diskussionsbeiträge, 6, Universität Potsdam.